ADMA Biologics FY2025 EPS Estimate Cut by Cantor Fitzgerald

ADMA Biologics, Inc. (NASDAQ:ADMA) – Analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for ADMA Biologics in a research note issued on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of $0.72 for the year, down from their prior forecast of $0.73. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business’s revenue was up 40.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.08 EPS.

Other equities research analysts have also recently issued research reports about the company. Raymond James lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday. StockNews.com cut ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Stock Performance

ADMA opened at $19.99 on Monday. The business’s 50 day moving average is $20.23 and its 200-day moving average is $18.76. The stock has a market cap of $4.75 billion, a PE ratio of 71.39 and a beta of 0.57. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics has a twelve month low of $8.42 and a twelve month high of $25.67.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after acquiring an additional 80,302 shares during the period. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after acquiring an additional 50,399 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock valued at $80,065,000 after acquiring an additional 643,661 shares during the period. Renaissance Technologies LLC increased its stake in shares of ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock valued at $64,654,000 after acquiring an additional 102,692 shares during the period. Finally, Perpetual Ltd acquired a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $62,300,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.